

Claire Trivin<sup>1</sup>, Marie Metzger<sup>2,3</sup>, Jean-Philippe Haymann<sup>4,5</sup>, Jean-Jacques Boffa<sup>5,6</sup>, Martin Flamant<sup>7,8</sup>, François Vrtovsnik<sup>8,9</sup>, Pascal Houillier<sup>10,11,12</sup>, Benedicte Stengel<sup>2 3</sup>, Eric Thervet<sup>1,12,13</sup>

<sup>1</sup> Department of Nephrology, Hôpital Européen G Pompidou, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France

<sup>2</sup> Inserm, CESP Centre for research in Epidemiology and Population Health, U1018, Team 10, Villejuif, France

<sup>3</sup>Université Paris Sud, UMRS 1018, F-94807, Villejuif, France

<sup>4</sup> Department of Physiology, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris,- Paris and Sorbonne Universités, UPMC Univ Paris 06

<sup>5</sup> Institut National de la Santé et de la Recherche Médicale, UMR-S 1155, Paris

<sup>6</sup> Department of Nephrology, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, Paris and Sorbonne Universités, UPMC Univ Paris 06

<sup>7</sup> Department of Physiology, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris

<sup>8</sup> Inserm U699, Paris

<sup>9</sup>Department of Nephrology, hôpital Bichat, Assistance Publique-Hôpitaux de Paris, université Pierre et Marie Curie, Paris

<sup>10</sup> Department of Physiology, Hôpital Européen G Pompidou, Assistance Publique-Hôpitaux de Paris.

<sup>11</sup>INSERM, Centre de Recherche des Cordeliers, UMR\_S1138, F-75006 Paris, France; CNRS, ERL8228, F-75006 Paris, France; Sorbonne Paris Cité, Université Paris Descartes, F-75006 Paris, France

<sup>12</sup>Renal and Cardiovascular Development and Pathophysiology. PARCC, Paris

<sup>13</sup>DHU Common and rare arterial disease

**Supplementary table 1: Multivariable analyses of overall mortality and pre-ESRD mortality.**

		HR (95%CI) overall mortality	HR (95%CI) pre-ESRD mortality
HbA <sub>1c</sub>	< 5.3 %	1(ref)	1(ref)
	5.3-5.6 %	1.07(0.61,1.88)	1.23(0.6,2.54)
	≥ 5.7 %	1.79(1.06,3.01)	2.00(1.02,3.92)
Age, year		1.07(1.05,1.09)	1.07(1.04,1.09)
Gender	Women vs Men	0.48(0.27,0.85)	0.29(0.14,0.62)
mGFR, ml/min/year		0.97(0.95,0.98)	0.96(0.95,0.98)
Origin	African-European vs other	0.24(0.05,1.03)	0.14(0.02,1.11)
	Missing vs other	1.94(0.79,4.77)	2.6(0.94,7.19)
BMI, kg/m <sup>2</sup>	< 19	4.74(2.1,10.69)	4.45(1.54,12.87)
	20-24	1(ref)	1(ref)
	25- 29	0.67(0.44,1.04)	0.57(0.33,0.98)
	≥ 30	0.65(0.33,1.29)	0.64(0.3,1.4)
Elevated blood pressure*	Yes vs no	1.29(0.85,1.96)	1.40(0.84,2.33)
History of CV Disease	Yes vs no	1.75(1.14,2.68)	1.52(0.89,2.62)
Smoking	Never	1(ref)	1(ref)
	Past	1.46(0.93,2.29)	1.14(0.66,1.97)
	Current	1.84(1.03,3.29)	1.61(0.75,3.47)
ACEi or ARB	Yes vs no treatment	0.97(0.63,1.51)	1.03(0.60,1.76)
	Missing vs no	0.91(0.30,2.80)	1.53(0.44,5.34)
Log (PCR)		0.95(0.78,1.16)	0.79(0.61,1.03)
Serum albumin	>3.5 g/dl vs <3.5 g/dl	1.58(0.89,2.8)	2.1(1.06,4.16)
Site	1 vs 3	1.53(0.36,6.59)	1.4(0.32,6.19)
	2 vs 3	2.54(0.6,10.78)	2.76(0.64,11.94)

\*Blood pressure >140/90

Abbreviations: mGFR, measured glomerular filtration rate; BMI, body mass index; CV, cardiovascular; ACEI, angiotensin converting enzyme inhibitor; ARB, antireceptor blocker; PCR Proteinuria to creatininuria ratio